Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements

COVID-19 drugs must be manufactured under good manufacturing practices (GMP) conditions. These conditions must be in line with the international requirements outlined in the International Council for Harmonization Q7A guideline and with applicable Health Canada's guidance.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Lignes directrices sur les exigences relatives aux autorisations de mise en marché des médicaments contre la COVID-19 : Exigences de qualité et de fabrication
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2021-10-29 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["COVID-19", "médicaments COVID-19", "exigences d'autorisation de mise sur le marché", "médicament fabriqué", "vendu", "processus réglementaire", "exigences de fabrication", "exigences de qualité"], "en": ["COVID-19", "COVID-19 drugs", "market authorization requirements", "drug manufactured", "sold", "regulatory process", "manufacturing requirements", "quality requirements"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source